Sildenafil Tablet, Film Coated
Product Images NDC 59746-471

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 59746-471). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000s (1000s Label)

Each film-coated tablet contains 20 mg of sildenafil citrate, USP. The usual dosage information can be found in the accompanying prescribing information. It is important to keep this medication out of reach of children and dispense in tight containers. Store between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). This medication is manufactured by Jubiant Generics Limited in Roorkee, India, and marketed by Jubiant Cadista Pharmaceuticals Inc. in Yardley, USA. Each bottle contains 1000 tablets of sildenafil, USP 20 mg. The product is available with the NDC 59746-471-10.*

FDA Label Image

500s (500s Label)

This is a description of sildenafil tablets containing 20 mg of sildenafil citrate. The tablets are film-coated and come in a pack of 500 tablets. The usual dosage instructions are not provided in the text, suggesting that they can be found in the accompanying prescribing information. The tablets are manufactured by Jubilant Generics Limited in India and marketed by Jubilant Cadista Pharmaceuticals Inc. in the USA. The text also includes storage instructions and details for dispensing the medication in tight containers. Additionally, there are batch details and a GTIN number provided for tracking purposes.*

FDA Label Image

Container (Container)

This text appears to be information about sildenafil tablets, USP, containing 20 mg of sildenafil. The usual dosage instructions are not available, and it is advised to refer to the accompanying prescribing information. The tablets should be stored at 20°C to 25°C (68°F to 77°F). The medication is manufactured by Jubilant Generics Limited in Roorkee, India, and marketed by Jubilant Cadista Pharmaceuticals Inc. in Yardley, PA, USA. The NDC code for the medication is 59746-471-90.*

FDA Label Image

Fig-1 (Fig 1)

This text provides recommendations for drug dosage adjustments when used in combination with Sildenafil. It includes information on various drugs such as Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir, detailing whether dose adjustments are needed. Additionally, it mentions AUC accumulation ratios and specifies that combining sildenafil with bosentan may not benefit exercise capacity.*

FDA Label Image

Fig08 (Fig08)

This text provides information on drug interactions and recommendations for dose adjustments. It includes details on various drugs such as Acenocoumarol, Aspirin, Atorvastatin, Doxazosin, Levonorgestrel, and more. The document also mentions specific dose adjustments and interactions for different medications. Additionally, it discusses the impact of combining drugs like sildenafil and bosentan on exercise capacity. The text offers valuable guidance for healthcare professionals managing drug therapies in patients.*

FDA Label Image

Fig09 (Fig09)

This text provides information on the change from baseline in meters for different doses of sildenafil (20 mg, 40 mg, and 80 mg) at different time points during the study (Week 8 and Week 12). The measurements are listed as changes in percentage. The data seems to be related to the efficacy or impact of sildenafil on the study subjects.*

FDA Label Image

Fig10 (Fig10)

This is a medical evaluation report providing information on a study involving the use of sildenafil at 20 mg three times a day for patients with idiopathic pulmonary arterial hypertension (PAH) of various etiologies. The report includes baseline walk distance data, patient demographics (including gender and age), mean pulmonary artery pressure (PAP), and changes in 6-minute walk distance under placebo-corrected conditions. The study appears to assess the impact of sildenafil on functional capacity in patients with different classes of PAH severity.*

FDA Label Image

Fig11 (Fig11)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.